Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.

Mutations on NHR (N-terminal heptad repeat) associated with resistance to fusion inhibitor were observed. In addition, mutations on CHR (C-terminal heptad repeat) accompanied NHR mutations of gp41 are noted in many cases, like N43D/S138A double mutation. In this work, we explored the drug resistant...

Full description

Bibliographic Details
Main Authors: Xueting Ma, Jianjun Tan, Min Su, Chunhua Li, Xiaoyi Zhang, Cunxin Wang
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4230944?pdf=render
id doaj-f52dfbe4aa5549708681055ed14d01f4
record_format Article
spelling doaj-f52dfbe4aa5549708681055ed14d01f42020-11-25T02:47:36ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01911e11192310.1371/journal.pone.0111923Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.Xueting MaJianjun TanMin SuChunhua LiXiaoyi ZhangCunxin WangMutations on NHR (N-terminal heptad repeat) associated with resistance to fusion inhibitor were observed. In addition, mutations on CHR (C-terminal heptad repeat) accompanied NHR mutations of gp41 are noted in many cases, like N43D/S138A double mutation. In this work, we explored the drug resistant mechanism of N43D mutation and the role of S138A second mutation in drug resistance. The binding modes of the wild type gp41 and the two mutants, N43D and N43D/S138A, with the HIV-1 fusion inhibitor C34, a 34-residue peptide mimicking CHR of gp41, were carried out by using molecular dynamics simulations. Based on the MD simulations, N43D mutation affects not only the stability of C34 binding, but also the binding energy of the inhibitor C34. Because N43D mutation may also affect the stable conformation of 6-HB, we introduced S138A second mutation into CHR of gp41 and determined the impact of this mutation. Through the comparative analysis of MD results of the N43D mutant and the N43D/S138A mutant, we found that CHR with S138A mutation shown more favorable affinity to NHR. Compelling differences in structures have been observed for these two mutants, particularly in the binding modes and in the hydrophobic interactions of the CHR (C34) located near the hydrophobic groove of the NHR. Because the conformational stability of 6-HB is important to HIV-1 infection, we suggested a hypothetical mechanism for the drug resistance: N43D single mutation not only impact the binding of inhibitor, but also affect the affinity between NHR and CHR of gp41, thus may reduce the rate of membrane fusion; compensatory mutation S138A would induce greater hydrophobic interactions between NHR and CHR, and render the CHR more compatible to NHR than inhibitors.http://europepmc.org/articles/PMC4230944?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Xueting Ma
Jianjun Tan
Min Su
Chunhua Li
Xiaoyi Zhang
Cunxin Wang
spellingShingle Xueting Ma
Jianjun Tan
Min Su
Chunhua Li
Xiaoyi Zhang
Cunxin Wang
Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
PLoS ONE
author_facet Xueting Ma
Jianjun Tan
Min Su
Chunhua Li
Xiaoyi Zhang
Cunxin Wang
author_sort Xueting Ma
title Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
title_short Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
title_full Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
title_fullStr Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
title_full_unstemmed Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.
title_sort molecular dynamics studies of the inhibitor c34 binding to the wild-type and mutant hiv-1 gp41: inhibitory and drug resistant mechanism.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Mutations on NHR (N-terminal heptad repeat) associated with resistance to fusion inhibitor were observed. In addition, mutations on CHR (C-terminal heptad repeat) accompanied NHR mutations of gp41 are noted in many cases, like N43D/S138A double mutation. In this work, we explored the drug resistant mechanism of N43D mutation and the role of S138A second mutation in drug resistance. The binding modes of the wild type gp41 and the two mutants, N43D and N43D/S138A, with the HIV-1 fusion inhibitor C34, a 34-residue peptide mimicking CHR of gp41, were carried out by using molecular dynamics simulations. Based on the MD simulations, N43D mutation affects not only the stability of C34 binding, but also the binding energy of the inhibitor C34. Because N43D mutation may also affect the stable conformation of 6-HB, we introduced S138A second mutation into CHR of gp41 and determined the impact of this mutation. Through the comparative analysis of MD results of the N43D mutant and the N43D/S138A mutant, we found that CHR with S138A mutation shown more favorable affinity to NHR. Compelling differences in structures have been observed for these two mutants, particularly in the binding modes and in the hydrophobic interactions of the CHR (C34) located near the hydrophobic groove of the NHR. Because the conformational stability of 6-HB is important to HIV-1 infection, we suggested a hypothetical mechanism for the drug resistance: N43D single mutation not only impact the binding of inhibitor, but also affect the affinity between NHR and CHR of gp41, thus may reduce the rate of membrane fusion; compensatory mutation S138A would induce greater hydrophobic interactions between NHR and CHR, and render the CHR more compatible to NHR than inhibitors.
url http://europepmc.org/articles/PMC4230944?pdf=render
work_keys_str_mv AT xuetingma moleculardynamicsstudiesoftheinhibitorc34bindingtothewildtypeandmutanthiv1gp41inhibitoryanddrugresistantmechanism
AT jianjuntan moleculardynamicsstudiesoftheinhibitorc34bindingtothewildtypeandmutanthiv1gp41inhibitoryanddrugresistantmechanism
AT minsu moleculardynamicsstudiesoftheinhibitorc34bindingtothewildtypeandmutanthiv1gp41inhibitoryanddrugresistantmechanism
AT chunhuali moleculardynamicsstudiesoftheinhibitorc34bindingtothewildtypeandmutanthiv1gp41inhibitoryanddrugresistantmechanism
AT xiaoyizhang moleculardynamicsstudiesoftheinhibitorc34bindingtothewildtypeandmutanthiv1gp41inhibitoryanddrugresistantmechanism
AT cunxinwang moleculardynamicsstudiesoftheinhibitorc34bindingtothewildtypeandmutanthiv1gp41inhibitoryanddrugresistantmechanism
_version_ 1724752645964431360